News and Trends 15 Apr 2019 First Stem Cell Therapy for Liver Failure Shows Promise in First Human Trials A stem cell therapy developed by the Belgian company Promethera has improved symptoms, such as jaundice, in patients with acute liver failure, a condition with no effective treatments. A phase I/IIa trial of the therapy recruited 19 patients with chronic liver disease. Of these,12 patients had developed acute-on-chronic liver failure, a life-threatening syndrome where the […] April 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2019 Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M After some big failures from its top competitors earlier this year, French company Genfit has done an IPO to prepare the launch of its drug for NASH, a chronic liver disease for which there is currently no treatment. Today, Genfit has started trading on Nasdaq. Together with issuing new shares in its existing Euronext Paris […] March 27, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2018 NASH Leader goes Pediatric with Clinical Trial Launch in US The FDA has cleared Genfit to kick off clinical trials to see if its NASH drug, elafibranor, can also help children. Genfit develops diagnostic and therapeutic tools for metabolic and inflammatory diseases, particularly those affecting the liver. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH), and the company’s plan to begin testing it in children has been supported […] January 23, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2017 Bored Between the Holidays? Watch these Biotech Videos! Christmas might have passed, but we have more videos for you to watch on a dreary winter day! Here are our highlights from 2017. It’s vacation time! If you’ve worn out the holiday movies, catch up on our biotech ones. It was a busy year, and we produced a lot, thanks to our new Hangouts […] December 28, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Dec 2017 Interviews, Reviews and Tops: Our Best Biotech Articles from 2017 We love hearing from our readers, and we listen to what they like! Here are the long reads from our best biotech articles of 2017. We gave you a list of books to read this holiday season, but do you need something lighter for the post-Christmas daze? We’ve collected our most popular long articles of […] December 26, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2017 New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH NorthSea Therapeutics has been founded in the Netherlands to develop a drug against NASH, a disease with no treatment and a huge market. With a €25M investment in Series A, NorthSea Therapeutics is all set to start Phase II trials in nonalcoholic steatohepatitis (NASH) and take on a very profitable market. The fundraising was led by Forbion […] December 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2017 PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody ChemomAb kicked off its antibody efforts as a company in 2011, and its $10M Series B has attracted none other than Peter Thiel. Israeli biotech has been attracting quite sizeable funds recently, largely those of UK investment outfit Arix Bioscience. Yesterday it was announced that Peter Theil, co-founder of PayPal and assassin of Gawker, led […] December 5, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 Nov 2017 NASH Leader Signs Up for EU Project to Fight Deadly Liver Disease Update 27/11/17: Genfit, the leader in the fight against NASH, has joined the LITMUS study. The company will share its experience and resources with the EU collaboration by contributing samples from its RESOLVE-IT clinical study. Genfit will co-lead two projects in patient recruitment and specialized biomarker assays, focusing on genetics and miRNA. Originally published: 23/11/17 […] November 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […] November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2017 Genfit Gets €180M Cash Injection to Bring its Pipeline to Market Elafibranor, Genfit’s lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a leader in the development of diagnostic tools and therapeutics for metabolic and inflammatory diseases. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH) – an inflammatory disease of the liver. The company has raised €180M by selling bonds […] October 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Sep 2017 These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare Biotech is the best source of innovation in R&D, making its companies the darlings of pharma. Which therapeutic fields belong to biotech? “Biotech is typically first in highly innovative fields,” Matt Kapusta, CEO of uniQure told us. Before he became CEO, uniQure brought the world’s first gene therapy to market — completely on its own. Biotech […] September 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 11 Jul 2017 The Advantage for the First Mover in NASH is Limited, says Genfit After we reviewed NASH earlier this year, Genfit’s CSO, Dean Hum, came to speak at Refresh about his company’s strategy in the space. As CSO of Genfit, Dean Hum coordinates the company’s R&D efforts to be first to market in NASH, which represent an untapped market of €37B. The company is counting on its lead […] July 11, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email